To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Knee OA: Intraarticular injections of PRP show no benefit over HA over a 12 month period

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
September 2015

Knee OA: Intraarticular injections of PRP show no benefit over HA over a 12 month period

Vol: 4| Issue: 9| Number:34| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Platelet-Rich Plasma Intra-articular Knee Injections Show No Superiority Versus Viscosupplementation: A Randomized Controlled Trial

Am J Sports Med. 2015 Jul;43(7):1575-82

Contributing Authors:
G Filardo B Di Matteo A Di Martino ML Merli A Cenacchi P Fornasari M Marcacci E Kon

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

192 patients with unilateral osteoarthritis or chondropathy of the knee were randomized to receive 3 intra-articular injections of either hyaluronic acid or platelet-rich plasma. The purpose of the study was to compare the two treatments in terms of clinical results up to 12 months after treatment in this patient population. Results indicated significant benefits of both treatments in all clinical...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue